PUBLICATION
Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription
- Authors
- Zou, G., Zhang, X., Wang, L., Li, X., Xie, T., Zhao, J., Yan, J., Wang, L., Ye, H., Jiao, S., Xiang, R., Shi, Y.
- ID
- ZDB-PUB-200620-2
- Date
- 2020
- Source
- Theranostics 10: 6839-6853 (Journal)
- Registered Authors
- Keywords
- Emodin/NCOR2/SerRS/tumor angiogenesis/VEGFA
- MeSH Terms
-
- Angiogenesis Inhibitors/pharmacology*
- Animals
- Breast Neoplasms/drug therapy*
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Cell Line, Tumor
- Cell Movement
- Disease Models, Animal
- Emodin/pharmacology*
- Female
- Gene Expression Regulation, Neoplastic*
- Herbal Medicine/methods*
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Inbred NOD
- Mice, SCID
- Neovascularization, Pathologic/metabolism
- Neovascularization, Pathologic/pathology
- Neovascularization, Pathologic/prevention & control*
- Protein Kinase Inhibitors/pharmacology
- Serine-tRNA Ligase/metabolism
- Vascular Endothelial Growth Factor A/genetics*
- Vascular Endothelial Growth Factor A/metabolism
- Zebrafish/metabolism
- PubMed
- 32550907 Full text @ Theranostics
Citation
Zou, G., Zhang, X., Wang, L., Li, X., Xie, T., Zhao, J., Yan, J., Wang, L., Ye, H., Jiao, S., Xiang, R., Shi, Y. (2020) Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics. 10:6839-6853.
Abstract
Anti-angiogenesis is an important and promising strategy in cancer therapy. However, the current methods using anti-vascular endothelial growth factor A (VEGFA) antibodies or inhibitors targeting VEGFA receptors are not as efficient as expected partly due to their low efficiencies in blocking VEGFA signaling in vivo. Until now, there is still no method to effectively block VEGFA production in cancer cells from the very beginning, i.e., from the transcriptional level. Here, we aimed to find bioactive small molecules to block VEGFA transcription. Methods: We screened our natural compound pool containing 330 small molecules derived from Chinese traditional herbs for small molecules activating the expression of seryl-tRNA synthetase (SerRS), which is a newly identified potent transcriptional repressor of VEGFA, by a cell-based screening system in MDA-MB-231 cell line. The activities of the candidate molecules on regulating SerRS and VEGFA expression were first tested in breast cancer cells. We next investigated the antiangiogenic activity in vivo by testing the effects of candidate drugs on the vascular development in zebrafish and by matrigel plug angiogenesis assay in mice. We further examined the antitumor activities of candidate drugs in two triple-negative breast cancer (TNBC)-bearing mouse models. Furthermore, streptavidin-biotin affinity pull-down assay, coimmunoprecipitation assays, docking analysis and chromatin immunoprecipitation were performed to identify the direct targets of candidate drugs. Results: We identified emodin that could greatly increase SerRS expression in TNBC cells, consequently reducing VEGFA transcription. Emodin potently inhibited vascular development of zebrafish and blocked tumor angiogenesis in TNBC-bearing mice, greatly improving the survival. We also identified nuclear receptor corepressor 2 (NCOR2) to be the direct target of emodin. Once bound by emodin, NCOR2 got released from SerRS promoter, resulting in the activation of SerRS expression and eventually the suppression of VEGFA transcription. Conclusion: We discovered a herb-sourced small molecule emodin with the potential for the therapy of TNBC by targeting transcriptional regulators NCOR2 and SerRS to suppress VEGFA transcription and tumor angiogenesis.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping